Board of Directors
Chairman of the Board
Mr. Gabrieli has served on Akcea’s board of directors since April 2016. Mr. Gabrieli is chief executive officer of Empower Schools, a non‑profit education innovation organization, and since May 2014, Mr. Gabrieli has served as a Partner Emeritus at Bessemer Venture Partners, a venture capital fund. Previously, from 1987 to April 2014, Mr. Gabrieli was a Partner at Bessemer, where he led their life sciences practice and made a founding investment Ionis. Mr. Gabrieli served on Ionis’ board of directors from 1989 to 2006. During his time at Bessemer, he invested in more than thirty life science and health care companies, including several that became publicly traded. Mr. Gabrieli is also the Chairman of the Massachusetts Board of Higher Education and a part‑time Lecturer at the Harvard Graduate School of Education.
Edward M. Fitzgerald
Mr. Fitzgerald has over 35 years of business, financial and accounting experience, with 20 years of experience in the pharmaceutical and biotechnology industry. He has been an independent business advisor since 2016. From 2010 to 2016, Mr. Fitzgerald served as executive vice president, chief financial officer and treasurer of ARIAD Pharmaceuticals, Inc., an international biopharmaceutical company, and served as the company’s senior vice president, chief financial officer and treasurer from 2002 to 2010. At ARIAD, Mr. Fitzgerald managed the growth and expansion of the company from a research-stage organization to an international commercial company with operations in the U.S. and multiple countries in Europe, managing over $1.2 billion in capital raises and other financings. Prior to ARIAD, Mr. Fitzgerald served as senior vice president, chief financial officer and secretary of AltaRex, Inc., a development stage biotechnology company, from 1998 to 2002. From 1992 to 1997, he held management positions at BankBoston Corporation in its mergers & acquisitions group and its consumer lending group. From 1989 to 1992, Mr. Fitzgerald was a partner in the audit and business advisory practice of Arthur Andersen & Co.
Sandford (“Sandy”) D. Smith
Mr. Smith has served as a member of Akcea’s board of directors since March 2017. For the past 20 years, he has focused on drugs and therapies for rare genetic diseases. Mr. Smith founded Global Biolink Partners and serves as chairman. From July 2015 to January 2016, Mr. Smith served as Aegerion’s interim chief executive officer, and following Aegerion’s merger with Novelion, he vice vhairman of Novelion. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as executive vice president of Genzyme, and president of Genzyme International. From 1986 to 1996, Mr. Smith was president, chief executive officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, culminating as vice president of business development and strategic planning for the pharmaceutical and nutritional Division. He currently serves on the boards of Cytokinetics Inc., Apricus Biosciences and Neuralstem Inc., each a publicly traded biopharmaceutical company.
Ms. Hochberg has served as a member of Akcea’s board of directors since March 2017. Currently, Ms. Hochberg is a managing partner of Elaran, LLC, a business strategy and management firm. She has 30 years of experience in the pharmaceutical industry commercializing a wide array of products in the United States and international markets. Ms. Hochberg served in various senior leadership positions at Forest Laboratories from June 1997 to June 2014 when the company was sold to Actavis. Her roles included executive vice president of international, strategic planning and government affairs from 2013 to 2014; executive vice president, US sales and marketing; chief commercial officer from 2010 to 2013; senior vice president of marketing and chief commercial officer from 2007 to 2010; senior vice president of marketing from 1999 to 2007; and vice president of marketing from 1997 to 1999. Ms. Hochberg began her pharmaceutical career in July of 1985 at Sandoz Pharmaceuticals (now Novartis). In April of 1991, she joined Wyeth-Ayerst Laboratories (now Pfizer) where she held several positions of increasing responsibility, ultimately serving as assistant vice president of marketing of the company’s vaccines and pediatrics division. She also serves on the boards of several nonprofit organizations in the New York City area.
B. Lynne Parshall, J.D.
Ms. Parshall is director and chief operating officer of Ionis Pharmaceuticals. She is responsible for overseeing the operations of finance, legal, patents, manufacturing, information technology, regulatory and alliance management, health and safety, facilities, corporate communications, and business and corporate development. Ms. Parshall joined Ionis in November 1991.
Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley LLP, where she represented several health care companies in a general practice specializing in corporate partnering and other technology-based transactions.
Ms. Parshall received her J.D. at Stanford Law School and her B.A. from Harvard University, and is a member of the American, California and San Diego bar associations. Ms. Parshall also serves on the Board of Cytokinetics, Inc., and is a member of the Licensing Executives Society.
Damien McDevitt, Ph.D.
Dr. McDevitt is currently Ionis’ chief business officer responsible for leading Ionis’ corporate development activities, including business development, competitive intelligence, alliance management, investor relations and corporate communications. He joined Ionis in June 2018 from ACADIA Pharmaceuticals, where he served as senior vice president, corporate development. Prior to joining ACADIA, Dr. McDevitt spent more than two decades at GSK in a variety of global and strategic business roles where he was instrumental in completing more than 70 transactions, building and supporting the commercial business, and helping to drive the strategic expansion of GSK in the western US and Asia. He has served in various roles with increasing responsibility including vice president, head of Business Development for R&D Extended Therapy Areas, head of Worldwide Business Development Asia and head of GSK’s R&D West Coast Innovation Center. He also worked at GSK Ventures and in Anti-Infective discovery. Dr. McDevitt is an author of 70 scientific publications and published patents. He attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and undergraduate degree, both in microbiology.
Richard A. Moscicki, M.D.
Dr. Moscicki has served as a member of Akcea’s board of directors since June 2018. Dr. Moscicki has been the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA) since he joined in 2017. From 2013 to 2017, prior to joining PhRMA, Dr. Moscicki served as Deputy Center Director for Science Operations for the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). He was senior vice president and Head of Clinical Development at Sanofi-Genzyme from 2011-2013. Dr. Moscicki served as Chief Medical Officer at Genzyme Corporation from 1992 to 2011 where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs. Dr. Moscicki received his medical degree from Northwestern University Medical School.
Ms. Soteropoulos is a global strategic and operating management executive with nearly 30 years of experience and success building high-performance global teams, leading complex development programs from early stage through approval, and commercializing global products. Ms. Soteropoulos joined Akcea as President and Chief Executive Officer upon its formation in January 2015. Prior to joining Akcea, Ms. Soteropoulos was a member of the executive leadership team of Moderna Therapeutics as the Cardiometabolic Business Unit General Manager and Senior Vice President of Strategic Alliances. Prior to Moderna, she spent 21 years at Genzyme Corporation where she was instrumental in advancing new products from discovery through clinical development and commercialization, with significant roles driving strategy, sales and marketing, and business development. Additionally, she led manufacturing process development, strategic capacity planning, and supply chain development. Prior to Genzyme, Ms. Soteropoulos was a bioprocess engineering consultant for various biopharmaceutical companies. She serves on the Board of Directors of uniQure B.V. and on the Advisory Board of the Tufts University Chemical and Biological Engineering Department. Ms. Soteropoulos earned her B.S. and Master’s degrees in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia. She is also a past honoree of Mass High Tech’s Women to Watch.
Sarah Boyce is an experienced commercial leader with over 25 years of experience in the life sciences industry, who has overseen both specialty pharmaceutical divisions and global commercial operations.
Ms. Boyce joined Akcea as a board member in March 2018. Previously, Ms. Boyce was the Chief Business Officer of Ionis Pharmaceuticals. In this role Ms. Boyce was responsible for overseeing the operations of investor relations and corporate communications, business development, alliance management, competitive intelligence and patient advocacy. Notably, she led Ionis activity to drive the strategic collaboration with Novartis, announced in January 2017, which established an exclusive, worldwide option and collaboration agreement regarding the development and commercialization of two therapeutic candidates now in Akcea’s pipeline. Ms. Boyce joined Ionis in January 2015.
Previously, Ms. Boyce was vice president, head of international business strategy and operations at Forest Laboratories, Inc. where she led launches in addition to development and expansion of their international pharmaceutical and consumer health businesses. Prior to Forest, she served as a global business leader for Alexion and Novartis, where she held a number of roles of increasing responsibility. During these roles, Ms. Boyce was involved in the commercializing of multiple blockbuster pharmaceuticals including Forest Laboratories’ Colobreathe®, Alexion’s Soliris® and Novartis’ Gleevec® and Tasigna®.
Ms. Boyce received her B.S. degree in microbiology from the University of Manchester, England.